Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fluticasone Spray Competition Grows With Perrigo Launch Of West-Ward Product

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Hikma Pharmaceuticals subsidiary West-Ward Pharmaceuticals' ANDA for fluticasone propionate/0.05mg per spray and Perrigo is shipping the generic equivalent of Flonase Allergy Relief to retailers and distributors.

You may also be interested in...



GSK Rides Cold, Flu And Pain OTCs In Q4 While Allergy Carries Sanofi

Firm's "power brands" in respiratory and pain areas achieved high single-digit sales growth in the fourth quarter on an “earlier and more severe” cold season that also drove overall consumer health sales in the period up 4.3% to $2.65bn.

GSK Rides Cold, Flu And Pain OTCs In Q4 While Allergy Carries Sanofi

Firm's "power brands" in respiratory and pain areas achieved high single-digit sales growth in the fourth quarter on an “earlier and more severe” cold season that also drove overall consumer health sales in the period up 4.3% to $2.65bn.

OTCs Launched On Fluticasone ANDAs, Lidocaine In Monograph

Innovus entering OTC fluticasone market in November; and Rising Biosciences prepares topical OTC pain relief.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel